Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) has provided an update.
Qiagen disclosed a managers’ transaction under EU market abuse regulations involving supervisory board member Bert van Meurs. He was granted 4,618 restricted stock units linked to Qiagen shares on February 27, 2026, in a transaction executed outside a trading venue and connected to the company’s share-based incentive programs.
The award of restricted stock units underscores Qiagen’s continued use of equity-linked compensation to align management and board interests with shareholders. Such grants are standard in listed companies and signal ongoing commitment to governance practices that tie leadership rewards to long-term share performance and corporate value creation.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences and molecular diagnostics company whose shares trade on several European exchanges, as well as the NYSE and Swiss markets. The company provides sample and assay technologies used in molecular testing, serving clinical diagnostics, pharmaceutical research, and applied testing markets worldwide.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.